Related Experiment Videos

Structure-activity relationship of verapamil analogs and reversal of multidrug resistance

G Toffoli1, F Simone, G Corona

  • 1Division of Experimental Oncology 1, Centro di Riferimento Oncologico, Aviano, Italy.

Biochemical Pharmacology
|October 12, 1995
PubMed

Insights

Researchers explored how chemical structure affects multidrug resistance (MDR) reversal in cancer. Specific structural features, like 7-cyan-8-methyl groups, enhance MDR reversal by interacting with P-glycoprotein (P-gp).

Area of Science:

  • Pharmacology
  • Medicinal Chemistry
  • Cancer Biology

Background:

  • Multidrug resistance (MDR) is a major challenge in cancer chemotherapy, often mediated by P-glycoprotein (P-gp) efflux pumps.
  • Verapamil (VER) and its analogs (VAs) are known to modulate P-gp activity, but structure-activity relationships for MDR reversal are not fully elucidated.

Purpose of the Study:

  • To investigate the relationship between the chemical structure of verapamil analogs and their ability to reverse multidrug resistance in a human colon carcinoma cell line.
  • To identify key structural features responsible for MDR reversal activity and cytotoxic effects.

Main Methods:

  • Utilized the LoVo-R human colon carcinoma cell line, which overexpresses the MDR1 gene product, as an experimental model for MDR.
  • Synthesized and tested 14 verapamil analogs for their ability to reverse doxorubicin resistance and their cytotoxic effects.
  • Assessed P-glycoprotein interaction using [3H]azidopine photolabeling inhibition and measured drug uptake.

Main Results:

  • Methoxy groups in verapamil analogs were found to prevent cytotoxicity when used alone.
  • The 7-cyan-8-methyl groups were crucial for MDR reversal activity and P-gp interaction.
  • Gallopamil, R-verapamil (R-VER), and nor-verapamil demonstrated significant potentiation of doxorubicin cytotoxicity, comparable to verapamil.
  • High reversal potency was observed with R-VER and nor-VER, which also exhibited lower calcium antagonist activity than verapamil.

Conclusions:

  • Specific structural modifications of verapamil can yield potent MDR reversal agents with potentially reduced side effects.
  • R-verapamil and nor-verapamil are promising candidates for further investigation in the treatment of multidrug-resistant cancers.
  • Understanding structure-activity relationships is key to designing effective MDR reversal therapies.

Related Concept Videos